Pioneering approach
Unique HDAC inhibitor platform
Cereno Scientific is pioneering the development of treatments for cardiovascular and pulmonary diseases using epigenetic modulation, a cutting-edge approach that focuses on changing gene expression without altering the underlying genetic code. This unique platform includes two promising drug candidates, CS1 and CS014, both of which leverage HDAC inhibition to offer a novel pathway for treating cardiovascular and pulmonary conditions.
Changing gene expression
Understanding epigenetic modulation
Epigenetic modulation refers to the process of changing how genes are expressed within cells, influencing how the body’s DNA is used to produce proteins. Unlike genetic mutations, epigenetic changes don’t alter the DNA sequence itself, but they can still have significant effects on cell function and disease risk. One of the key players in this process is histone deacetylase (HDAC), a family of enzymes found in almost all cells. By regulating the activity of HDACs, it is possible to impact various cellular mechanisms, which can, in turn, affect disease development.
Potential in diseases with significant unmet needs
A Novel Approach to Cardiovascular Disease
While epigenetic modulation has already shown promise in the treatment of cancer, its application in cardiovascular and pulmonary diseases is still in its early stages. However, recent advancements have demonstrated the potential of HDAC inhibitors to regulate disease-causing epigenetic changes, offering a new approach for therapeutic development in cardiovascular disease. HDAC inhibitors work by binding to HDAC enzymes, blocking their function, and exerting disease-modifying effects that could alter the course of cardiovascular and pulmonary conditions. Cereno Scientific is among the first biotechnology companies to harness the potential of Class I HDAC inhibitors for treating these diseases. This approach not only targets key pathological processes like fibrosis, inflammation, and hypertrophy but also shows strong cardioprotective effects, positioning Cereno Scientific’s drug candidates as promising candidates for addressing significant unmet medical needs in these therapeutic areas.
Explore more
Scientific Publications
Scientific publications
Explore scientific publications and abstracts that support and document the Company’s research and development.
Learn more
Driving excellence
Science & Pipeline
Cereno Scientific's pipeline is focused on innovative epigenetic modulating HDAC inhibitors.
Learn more